Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Oct;35(10):1961-7.
doi: 10.2337/dc12-0638.

PAI-1 and diabetes: a journey from the bench to the bedside

David J Schneider  1 , Burton E Sobel
Affiliations

PAI-1 and diabetes: a journey from the bench to the bedside

David J Schneider et al. Diabetes Care. 2012 Oct.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effects of increased concentrations of PAI-1. In blood (A) PAI-1 inhibits the action of t-PA, largely associated with clots, and thus attenuates the activity of the fibrinolytic system. In tissue (B), PAI-1attenuates activation of matrix metalloproteinases (MMPs) by plasmin generated from plasminogen by urokinase; plaques formed when PAI-1 is increased are likely to be prone to rupture. ECM, extracellular matrix; uPA, urokinase plasminogen activator.
Figure 2
Figure 2
Increased PAI-1 concentration is demonstrated by the intensity of brown immunohistochemical staining of specimens of diseased coronary arteries from representative patients with type 2 diabetes (top row) when compared with similar specimens from representative patients without diabetes (bottom row). Negative controls, obtained with the use of normal murine IgG instead of primary antibody against PAI-1, showed no detectable staining (data not shown). Magnification ×100. The figure is adapted with permission from Sobel et al. (21). (A high-quality digital representation of this figure is available in the online issue.)
Figure 3
Figure 3
Comparison of insulin-sensitizing (IS) with insulin-providing (IP) treatment strategies in 2,368 patients with type 2 diabetes and clinically stable coronary artery disease for an overall treatment interval of 5 years in the BARI 2D trial (44). The insulin-sensitizing strategy led to lower concentrations of both PAI-1 activity (A) and antigen (B). Baseline values for PAI-1 activity and PAI-1 antigen (16 AU/mL and 23 ng/mL, respectively) were the same for both the insulin-sensitizing and insulin-providing treatment groups.
See this image and copyright information in PMC

References

    1. Himsworth HP. Management of Diabetes Mellitus. BMJ 1936;2:137–141 - PMC - PubMed
    1. Greenland P, Alpert JS, Beller GA, et al. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2010;122:e584–e636 - PubMed
    1. Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985;313:1557–1563 - PubMed
    1. McGill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 1994;43:104–109 - PubMed
    1. Sobel BE. Increased plasminogen activator inhibitor-1 and vasculopathy. A reconcilable paradox. Circulation 1999;99:2496–2498 - PubMed

MeSH terms

Substances